CompletedNCT00446992
Blood sugar and weight changes after starting antipsychotic treatment
About this title
Read the official source — NCT00446992Medication studyAges 18–64SpainSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 64 years.
What did participation involve?
The study group receives olanzapine as a study medication.
- Listed locations
- BarcelonaSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateApril 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 30
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Spain
- Age range
- From 18 Years to 64 Years
- Official registry ID
- NCT00446992
- Official title
Show the full official title
Metabolic Effects of Olanzapine in Patients With Newly Diagnosed Psychosis
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Barcelona
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a research institute.
Did this study involve medication?
Yes. The study involved medication, including Olanzapine.
Who was this study for?
Listed age limits: 18 years to 64 years.
